Breakthrough's Research into Ovarian Cancer

Posted on: 09 Nov 2017

Breakthrough's Research into Ovarian Cancer

Ovarian cancer remains the leading cause of death among gynaecologic malignancies and the fifth leading cause of death among all cancers in women. Although the majority of women exhibit an excellent response to first line chemotherapy, approximately 80% of patients experience disease recurrence, characterised by multiple drug resistance. Due to the poor survival of women with recurrent, chemoresistant ovarian cancer, Breakthrough believe that a greater understanding of the mechanisms which contribute to this resistance is urgently needed.

 

During 2016, Ms. Jennifer Quinn was appointed as an Ovarian Research Fellow. Her role is supported by both the Brid Carr memorial fund and Breakthrough, and was set up to address the lack of awareness of and research into, ovarian cancer in Ireland. The memorial fund was established by the family of Brid Carr, who passed away from ovarian cancer. Jennifer is working with the Autophagy Team led by Dr Sharon McKenna and is thrilled to be part of our multidisciplinary group trying to tackle this lethal cancer.

 

Jennifer states, “My research aims to provide valuable insights into the molecular mechanisms of autophagy in ovarian cancer cells and provide a new understanding of its potential role in helping these cells to recover following treatment. By learning how to best modulate autophagy, it is hoped to improve patient outcomes via overcoming chemoresistance

 

We are excited to have Jennifer and her passion for scientific advancement on the Breakthrough team and are very thankful to Brid Carr’s family and friends for their vital support for this position.

© Site Designed by Granite Digital